{"classes":[{"categories":[{"measurements":[{"comment":"Upper boundary was not estimated due to the limited number of participants with events.","groupId":"OG000","lowerLimit":"4.03","upperLimit":"NA","value":"8.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"Time to progression was defined as the time from initiation of therapy to progressive disease (PD). PD requires at least one of the following:\n\n* \\>25% increase in serum monoclonal paraprotein (which must also be an absolute increase of at least 5 g/L),\n* \\>25% increase in 24-hour urinary light chain excretion (which must also be an absolute increase of at least 200 mg/24 h),\n* \\>25% increase in plasma cells in a bone marrow aspirate or on trephine biopsy (which must also be an absolute increase of at least 10%),\n* definite increase in the size of existing lytic bone lesions or soft tissue plasmacytomas,\n* the development of new bone lesions or soft tissue plasmacytomas,\n* the development of hypercalcemia (corrected serum calcium \\> 11.5 mg/dL or 2.8 mmol/L not attributable to any other cause).","dispersionType":"95% Confidence Interval","groups":[{"description":"Bendamustine in escalating doses of 50, 70 or 90 mg/m\\^2 as combination therapy with bortezomib at 1.0 mg/m\\^2/dose administered for up to eight 28 day cycles. Participants whose disease has not progressed at the end of the eight cycles will be followed until disease progression or death.","id":"OG000","title":"Bendamustine and Bortezomib - Overall"}],"paramType":"MEDIAN","populationDescription":"Safety population","reportingStatus":"POSTED","timeFrame":"up to 8.6 months","title":"Kaplan-Meier Estimate for Time to Progression (TTP)","type":"SECONDARY","unitOfMeasure":"months"}